Aytu BioPharma (AYTU) News Today $2.36 +0.17 (+7.76%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$2.38 +0.02 (+1.06%) As of 10/7/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AYTU Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Aytu BioPharma management to meet with Lake StreetOctober 1, 2025 | msn.comWall Street Zen Downgrades Aytu BioPharma (NASDAQ:AYTU) to HoldSeptember 28, 2025 | americanbankingnews.comMaxim Group Cuts Aytu BioPharma (NASDAQ:AYTU) Price Target to $7.00September 27, 2025 | americanbankingnews.comAscendiant Capital Maintains Aytu BioPharma (AYTU) Buy RecommendationSeptember 26, 2025 | msn.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2025 Earnings Call TranscriptSeptember 25, 2025 | insidermonkey.comAytu BioPharma, Inc.: Aytu BioPharma to Present at Upcoming September 2025 ConferencesSeptember 24, 2025 | finanznachrichten.deAytu BioPharma price target lowered to $7 from $9 at MaximSeptember 24, 2025 | msn.comAytu BioPharma Inc (AYTU) Q4 2025 Earnings Call Highlights: Strategic Moves and Financial ...September 24, 2025 | finance.yahoo.comAytu outlines EXXUA launch targeting $22B MDD market while streamlining ADHD portfolioSeptember 23, 2025 | msn.comAytu BioPharma, Inc. (AYTU) Q4 2025 Earnings Call TranscriptSeptember 23, 2025 | seekingalpha.comEarnings Scheduled For September 23, 2025September 23, 2025 | benzinga.comAytu BioPharma FQ4 2025 Earnings PreviewSeptember 22, 2025 | msn.comFDA targets drug marketing, advertising with slew of warning lettersSeptember 17, 2025 | msn.comBig pharma companies hit with FDA warning letters in drug ad clampdownSeptember 17, 2025 | finance.yahoo.comLake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA AcquisitionJuly 23, 2025 | msn.comAytu Boosts Liquidity with Eclipse Loan ExtensionJuly 2, 2025 | msn.comLake Street Initiates Coverage of Aytu BioPharma (AYTU) with Buy RecommendationJuly 2, 2025 | msn.comAscendiant Capital Initiates Coverage of Aytu BioPharma (AYTU) with Buy RecommendationJune 30, 2025 | msn.comAytu BioPharma, Inc.: Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA - FinanzNachrichten.deJune 27, 2025 | finanznachrichten.deAytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA (TM) - MorningstarJune 24, 2025 | morningstar.comMCEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More SharesJune 14, 2025 | finance.yahoo.comAytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class ...June 10, 2025 | morningstar.comMAytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in ...June 8, 2025 | seekingalpha.comAytu BioPharma, Inc.: Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common StockJune 6, 2025 | finanznachrichten.deAytu BioPharma Third Quarter 2025 Earnings: Beats ExpectationsMay 16, 2025 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comAytu BioPharma Stock Price, Quotes and Forecasts | NASDAQ:AYTU | BenzingaMay 15, 2025 | benzinga.comAytu signals ongoing portfolio expansion opportunities as Q3 2025 revenue surges 32%May 15, 2025 | msn.comAytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comAytu BioPharma Q3 Earnings PreviewMay 13, 2025 | msn.comAytu BioPharma’s treatment of Marfan syndrome receives FDA orphan designationApril 15, 2025 | markets.businessinsider.comAytu BioPharma, Inc. (NASDAQ:AYTU) CEO Acquires $19,500.00 in StockMarch 4, 2025 | insidertrades.comEarnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shiftsFebruary 13, 2025 | msn.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Call TranscriptFebruary 13, 2025 | msn.comAytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savingsFebruary 12, 2025 | seekingalpha.comAytu BioPharma, Inc. (AYTU) Q2 2025 Earnings Call TranscriptFebruary 12, 2025 | seekingalpha.comAytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial ResultsFebruary 12, 2025 | finanznachrichten.deAytu BioPharma Proposes Settlement in Shareholder LawsuitDecember 5, 2024 | finance.yahoo.comAytu BioPharma First Quarter 2025 Earnings: Beats ExpectationsNovember 16, 2024 | finance.yahoo.comAytu BioScience Announces Leadership Change and Financial GrowthNovember 15, 2024 | markets.businessinsider.comAytu BioPharma Reports Q1 Fiscal 2025 EarningsNovember 15, 2024 | markets.businessinsider.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call TranscriptNovember 15, 2024 | msn.comAytu BioPharma Names Ryan Selhorn as CFONovember 14, 2024 | marketwatch.comAytu BioPharma, Inc. (AYTU) Q1 2025 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comAytu BioPharma (NASDAQ:AYTU) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comAytu BioPharma inks deal with Lupin for ADHD drugs in CanadaOctober 3, 2024 | investing.comAytu BioPharma Full Year 2024 Earnings: EPS Misses ExpectationsSeptember 28, 2024 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2024 Earnings Call TranscriptSeptember 28, 2024 | msn.comAytu BioPharma files mixed offeringSeptember 27, 2024 | msn.comAnalysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before LongSeptember 8, 2024 | finance.yahoo.com Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AYTU Media Mentions By Week AYTU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AYTU News Sentiment▼0.000.55▲Average Medical News Sentiment AYTU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AYTU Articles This Week▼11▲AYTU Articles Average Week Get the Latest News and Ratings for AYTU and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aytu BioPharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies VolitionRx News ALT5 Sigma News Hyperion DeFi News InterCure News Gain Therapeutics News OS Therapies News Adlai Nortye News MiNK Therapeutics News MediciNova News Quantum Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AYTU) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredOctober 2025 Market Crash?Wall Street Legend Names #1 Stock [not NVDA] The greatest quantitative mind on Wall Street just revealed hi...Chaikin Analytics | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
